|
BioLife Solutions, a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, announced its participation at the IBC Inaugural Cell Therapy Clinical Development Conference taking place this week in Arlington, VA.
Dr. Aby J. Mathew, Senior Vice President and Chief Technology Officer, presented a lecture to dozens of executives and product development managers of commercial regenerative medicine companies. The presentation, titled, Optimizing Stability and Biopreservation for Cell Therapy Clinical Development and Bioprocessing, exposed the risk to clinical and commercial success of cell and tissue products due to stability limitations from the use of non-optimized storage, transport and cryopreservation freeze media. Compelling comparative data illustrating the superior preservation efficacy of BioLife's HypoThermosol® storage and shipping media, and CryoStor cryopreservation freeze media was presented on a broad spectrum of cell and tissue types.
Mike Rice, Chief Executive Officer, commented on BioLife's presence and leading supplier position within the regenerative medicine market: "Our participation at this event was validated by numerous other presenters for the first time, confirming to their peers and competitors that they have adopted our best-in-class biopreservation media products. We estimate that more than 60 percent of the companies registered to attend or present are current customers. It's very satisfying to see our quality environment and the ability of our products to improve cell-based therapies being recognized by the leaders in commercial cell therapy development."
For a list of upcoming events, please click here
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife onTwitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
|
RSS